Výsledky vyhledávání - Mattheus, Michaela

Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihy... Autor Zhu, Dingliang, Bays, Harold, Gao, Pingjin, Mattheus, Michaela, Voelker, Birgit, Ruilope, Luis M

Získat plný text Získat plný text Získat plný text

Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Ra... Autor Bays, Harold, Gao, Pingjin, Völker, Birgit, Mattheus, Michaela, Ruilope, Luis M., Zhu, Dingliang

Získat plný text Získat plný text Získat plný text

Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin Autor Troost, Joachim, Tatami, Shinji, Tsuda, Yasuhiro, Mattheus, Michaela, Mehlburger, Ludwig, Wein, Martina, Michel, Martin C

Získat plný text Získat plný text Získat plný text

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with t... Autor Kaku, Kohei, Wanner, Christoph, Anker, Stefan D., Pocock, Stuart, Yasui, Atsutaka, Mattheus, Michaela, Lund, Søren S.

Získat plný text Získat plný text Získat plný text

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials Autor Davidson, Jaime A, Lajara, Rosemarie, Aguilar, Richard B, Mattheus, Michaela, Woerle, Hans-Juergen, von Eynatten, Maximilian

Získat plný text Získat plný text Získat plný text

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial Autor Ferreira, João Pedro, Inzucchi, Silvio E., Mattheus, Michaela, Meinicke, Thomas, Steubl, Dominik, Wanner, Christoph, Zinman, Bernard

Získat plný text Získat plný text Získat plný text

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial Autor Fitchett, David, Inzucchi, Silvio E, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Vedin, Ola, Zinman, Bernard, Johansen, Odd Erik

Získat plný text Získat plný text Získat plný text

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes m... Autor Biessels, Geert Jan, Janssen, Jolien, van den Berg, Esther, Zinman, Bernard, Espeland, Mark A., Mattheus, Michaela, Johansen, Odd Erik

Získat plný text Získat plný text Získat plný text

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial Autor Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard

Získat plný text Získat plný text Získat plný text

HbA(1c), Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy Autor Janssen, Jolien, van den Berg, Esther, Zinman, Bernard, Espeland, Mark A., Geijselaers, Stefan L.C., Mattheus, Michaela, Johansen, Odd Erik, Biessels, Geert Jan

Získat plný text Získat plný text Získat plný text

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes Autor Ruggenenti, Piero, Kraus, Bettina J., Inzucchi, Silvio E., Zinman, Bernard, Hantel, Stefan, Mattheus, Michaela, von Eynatten, Maximilian, Remuzzi, Giuseppe, Koitka-Weber, Audrey, Wanner, Christoph

Získat plný text Získat plný text Získat plný text

Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis o... Autor Kadowaki, Takashi, Wang, Guang, Rosenstock, Julio, Yabe, Daisuke, Peng, Yongde, Kanasaki, Keizo, Mu, Yiming, Mattheus, Michaela, Keller, Annett, Okamura, Tomoo, Johansen, Odd Erik, Marx, Nikolaus

Získat plný text Získat plný text Získat plný text

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial Autor Verma, Subodh, Leiter, Lawrence A., Zinman, Bernard, Sharma, Abhinav, Mattheus, Michaela, Fitchett, David, George, Jyothis, Ofstad, Anne Pernille, Kosiborod, Mikhail N., Wanner, Christoph, Inzucchi, Silvio E.

Získat plný text Získat plný text Získat plný text

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial Autor Waijer, Simke W., Xie, Di, Inzucchi, Silvio E., Zinman, Bernard, Koitka‐Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximillian, Inker, Lesley A., Wanner, Christoph, Heerspink, Hiddo J. L.

Získat plný text Získat plný text Získat plný text

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial Autor Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, Butler, Javed

Získat plný text Získat plný text Získat plný text

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial Autor Wanner, Christoph, Heerspink, Hiddo J.L., Zinman, Bernard, Inzucchi, Silvio E., Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C., von Eynatten, Maximilian, Groop, Per-Henrik

Získat plný text Získat plný text Získat plný text

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Autor Zinman, Bernard, Inzucchi, Silvio E., Lachin, John M., Wanner, Christoph, Fitchett, David, Kohler, Sven, Mattheus, Michaela, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik, Albers, Gregory W., Diener, Hans Christoph

Získat plný text Získat plný text Získat plný text

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®)) Autor Marx, Nikolaus, Rosenstock, Julio, Kahn, Steven E, Zinman, Bernard, Kastelein, John J, Lachin, John M, Espeland, Mark A, Bluhmki, Erich, Mattheus, Michaela, Ryckaert, Bart, Patel, Sanjay, Johansen, Odd Erik, Woerle, Hans-Juergen

Získat plný text Získat plný text Získat plný text

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgrou... Autor Espeland, Mark A., Pratley, Richard E., Rosenstock, Julio, Kadowaki, Takashi, Seino, Yutaka, Zinman, Bernard, Marx, Nikolaus, McGuire, Darren K., Andersen, Knut Robert, Mattheus, Michaela, Keller, Annett, Weber, Maria, Johansen, Odd Erik

Získat plný text Získat plný text Získat plný text

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial Autor Rosenstock, Julio, Kahn, Steven E., Johansen, Odd Erik, Zinman, Bernard, Espeland, Mark A., Woerle, Hans J., Pfarr, Egon, Keller, Annett, Mattheus, Michaela, Baanstra, David, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K., Marx, Nikolaus

Získat plný text Získat plný text Získat plný text